Recombinant Human BACE1 cell lysate
Cat.No. : | BACE1-3006HCL |
Product Overview : | Human BACE1 / ASP2 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls |
- Specification
- Gene Information
- Related Products
Source : | Human cells |
Species : | Human |
Preparation method : | Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized. |
Lysis buffer : | Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF |
Quality control Testing : | 12.5% SDS-PAGE Stained with Coomassie Blue |
Recommended Usage : | 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating. |
Stability : | Samples are stable for up to twelve months from date of receipt at -80°C |
Storage Buffer : | 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF |
Storage Instruction : | Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes. |
Gene Name : | BACE1 beta-site APP-cleaving enzyme 1 [ Homo sapiens ] |
Official Symbol : | BACE1 |
Synonyms : | BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149; |
Gene ID : | 23621 |
mRNA Refseq : | NM_001207048 |
Protein Refseq : | NP_001193977 |
MIM : | 604252 |
UniProt ID : | P56817 |
Chromosome Location : | 11q23-q24 |
Pathway : | Alzheimers disease, organism-specific biosystem; Alzheimers disease, conserved biosystem; |
Function : | aspartic-type endopeptidase activity; beta-aspartyl-peptidase activity; enzyme binding; peptidase activity; |
Products Types
◆ Recombinant Protein | ||
Bace1-252M | Active Recombinant Mouse Bace1 protein(Met1-Thr457), His-tagged | +Inquiry |
BACE1-781H | Recombinant Human BACE1 Protein | +Inquiry |
BACE1-779H | Recombinant Human BACE1 Protein | +Inquiry |
BACE1-2200H | Recombinant Human BACE1 Protein, MYC/DDK-tagged | +Inquiry |
BACE1-253H | Active Recombinant Human BACE1 protein(Met1-Thr457), hFc-tagged | +Inquiry |
◆ Lysates | ||
BACE1-3077MCL | Recombinant Mouse BACE1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.
BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.
BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.
Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.
Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.
Customer Reviews (3)
Write a reviewSuch support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.
A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.
Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.
Ask a Question for All BACE1 Products
Required fields are marked with *
My Review for All BACE1 Products
Required fields are marked with *
Inquiry Basket